Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corp (RLYB) is a clinical-stage biotechnology company pioneering therapies for severe rare disorders through advanced modalities including antibodies and engineered proteins. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific progress and operational developments.
Access timely reports on clinical trial milestones, regulatory submissions, and strategic collaborations. Our curated collection features verified press releases, financial disclosures, and analysis of RLYB's innovative pipeline targeting conditions like fetal/neonatal alloimmune thrombocytopenia.
Key updates include progress on therapeutic candidates, partnership announcements with research institutions, and financial performance summaries. The resource is particularly valuable for tracking Rallybio's unique approach combining validated biological mechanisms with novel treatment strategies.
Bookmark this page for streamlined access to Rallybio's latest advancements in rare disease research. Check regularly for authoritative reporting on clinical developments and corporate announcements from this innovative biopharma leader.
Rallybio Corporation (Nasdaq: RLYB) announced its participation in two major investor conferences. The first is the Jefferies Healthcare Conference in New York on June 8, 2022, at 10:30 a.m. ET. The second is the JMP Securities Life Sciences Conference, also in New York, scheduled for June 15, 2022, at 10:30 a.m. ET. Investors can access a live webcast of both presentations through Rallybio’s website, with replays available for 30 days post-event. Rallybio focuses on therapies for severe and rare diseases, established in January 2018.
Rallybio Corporation (Nasdaq: RLYB) reported its Q1 2022 financial results, highlighting a net loss of $14.5 million, or $0.48 per share, compared to a net loss of $13.3 million in Q1 2021. The company initiated a Phase 1b study for RLYB212 targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT) and continues its Phase 1 study of RLYB116. Rallybio also acquired RLYB331 from Sanofi, aimed at treating severe anemias. R&D expenses decreased to $7.6 million, while G&A expenses rose to $6.7 million. Cash reserves stand at $161.4 million.
Rallybio Corporation (Nasdaq: RLYB) has secured worldwide exclusive rights to Sanofi's KY1066, now named RLYB331, a preclinical antibody targeting severe anemia linked to ineffective erythropoiesis and iron overload. This licensing agreement represents a significant development for Rallybio as it expands its hematology pipeline. RLYB331 aims to address unmet needs in patients with conditions like beta thalassemia and myelodysplastic syndromes. The company plans to initiate preclinical activities and will pay Sanofi $3 million upfront, along with additional milestone payments and royalties on sales.
Rallybio Corporation announces significant changes to its Board of Directors. Christine Nash and Hui Liu have been appointed as new members, bringing extensive experience in rare diseases and business development, respectively. Tim Shannon, M.D. will resign from the Board, effective at the 2022 Annual Meeting of Shareholders. The company aims to leverage the expertise of new board members to advance its product portfolio for rare diseases.
Rallybio Corporation (Nasdaq: RLYB) reported its 2021 financial results, highlighting a net loss of $47 million and increased R&D expenses of $26.9 million, driven by advancements in product candidates. The company is progressing with Phase 1 studies for RLYB212, targeting FNAIT, and RLYB116 for complement-related diseases, with initial data expected in 2022. Rallybio's cash position stood at $175.3 million as of December 31, 2021, supporting ongoing development efforts.
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company, announced that CEO Martin Mackay will participate in a panel discussion on 'Neuromuscular' at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event will be webcasted live on Rallybio's website, with an archived replay available for 30 days. Since its inception in January 2018, Rallybio aims to develop therapies for severe and rare diseases, focusing on hematology, immuno-inflammation, maternal fetal health, and metabolic disorders.
Rallybio Corporation (Nasdaq: RLYB) announced the appointment of Ami Bavishi as its new Head of Investor Relations and Corporate Communications. With over 10 years of experience, Bavishi will oversee the company's investor relations and communication strategies, reporting to Steven Tuch, Head of Corporate Development. Bavishi previously served as Director of Investor Relations at Aerie Pharmaceuticals. Rallybio, founded in January 2018, focuses on developing therapies for severe and rare diseases, with a strong pipeline in hematology and immuno-inflammation.
Rallybio Corporation (NASDAQ: RLYB) announced that the first subjects have been dosed in the Phase 1 study of RLYB212, targeting fetal and neonatal alloimmune thrombocytopenia (FNAIT). A proof-of-concept study is anticipated in Q3 2022. Additionally, they are set to initiate a Phase 1 study of RLYB116, a C5 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) and generalized Myasthenia Gravis (gMG), in Q1 2022. The company is also advancing an ENPP1 inhibitor with IND-enabling studies expected in Q2 2022, enhancing their commitment to developing therapies for severe and rare diseases.
Rallybio Corporation (Nasdaq: RLYB) reported promising results from its Phase 1/2 study of RLYB211, an anti-HPA-1a antibody aimed at preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). The data showed RLYB211 effectively eliminated HPA-1a mismatched platelets within 7 days, demonstrating a significant advantage over placebo. The study maintains a focus on safety and tolerability, confirming no serious adverse events. Rallybio plans to advance to the next phase with RLYB212, a monoclonal antibody targeting the same condition, with data expected mid-2022.
Rallybio (NASDAQ: RLYB), a clinical-stage biotechnology company, announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 8:00 a.m. ET. The company will engage in a virtual fireside chat and conduct one-on-one meetings on the same day. A webcast of the presentation will be available on Rallybio’s website, with an archived replay accessible for 30 days post-event. Founded in January 2018, Rallybio aims to develop therapies for severe and rare diseases across various medical fields.
